CN103436507B - 噬菌体衍生的抗微生物活性剂 - Google Patents

噬菌体衍生的抗微生物活性剂 Download PDF

Info

Publication number
CN103436507B
CN103436507B CN201310322283.7A CN201310322283A CN103436507B CN 103436507 B CN103436507 B CN 103436507B CN 201310322283 A CN201310322283 A CN 201310322283A CN 103436507 B CN103436507 B CN 103436507B
Authority
CN
China
Prior art keywords
polypeptide
amino acid
seqidno
phage
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310322283.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103436507A (zh
Inventor
S·帕德马纳巴恩
V·D·保罗
R·S·萨拉瓦纳
B·斯里拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berkeley Private Holdings Ltd
Original Assignee
Gangagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103436507(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gangagen Inc filed Critical Gangagen Inc
Publication of CN103436507A publication Critical patent/CN103436507A/zh
Application granted granted Critical
Publication of CN103436507B publication Critical patent/CN103436507B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
    • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
    • A01N47/44—Guanidine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201310322283.7A 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂 Expired - Fee Related CN103436507B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79788506P 2006-05-05 2006-05-05
US60/797,885 2006-05-05
US90934007P 2007-03-30 2007-03-30
US60/909,340 2007-03-30
CN2007800162540A CN101437532B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2007800162540A Division CN101437532B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Publications (2)

Publication Number Publication Date
CN103436507A CN103436507A (zh) 2013-12-11
CN103436507B true CN103436507B (zh) 2016-04-20

Family

ID=38668376

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310322283.7A Expired - Fee Related CN103436507B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN201610182492.XA Expired - Fee Related CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN2007800162540A Expired - Fee Related CN101437532B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610182492.XA Expired - Fee Related CN105884904B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂
CN2007800162540A Expired - Fee Related CN101437532B (zh) 2006-05-05 2007-05-04 噬菌体衍生的抗微生物活性剂

Country Status (10)

Country Link
US (6) US8202516B2 (https=)
EP (1) EP2037946B2 (https=)
JP (4) JP5383481B2 (https=)
CN (3) CN103436507B (https=)
CA (1) CA2651125C (https=)
DK (1) DK2037946T3 (https=)
ES (1) ES2536852T3 (https=)
MX (1) MX2008014150A (https=)
PT (1) PT2037946E (https=)
WO (1) WO2007130655A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007061929A1 (de) * 2007-12-21 2009-06-25 Profos Ag Proteasestabile Zellwand lysierende Enzyme
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
CA2739717A1 (en) * 2008-10-10 2010-04-15 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
EP2338916A1 (en) 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
EP2397548A1 (en) 2010-06-18 2011-12-21 Hyglos Invest GmbH Methods of generating and screening for lytic chimeric polypeptides
SG188566A1 (en) * 2010-09-17 2013-04-30 Tecnifar Ind Tecnica Farmaceutica S A Antibacterial phage, phage peptides and methods of use thereof
CN103635584B (zh) 2011-04-12 2017-10-27 冈戈根股份有限公司 嵌合抗菌多肽
PL394619A1 (pl) 2011-04-19 2012-10-22 Miedzynarodowy Instytut Biologii Molekularnej I Komórkowej Sposób proteolizy, peptydaza, kompozycja do stosowania jako srodek bakteriostatyczny lub bakteriobójczy, zestaw oraz zastosowania aktywnej formy LytM z S. aureus lub jej pochodnej
BR112014023176B1 (pt) * 2012-03-27 2021-09-28 Genentech, Inc. Métodos de produção de uma proteína recombinante
KR101466620B1 (ko) 2012-06-22 2014-11-28 주식회사 씨티씨바이오 신규한 박테리오파지 및 이의 아에로모나스 히드로필라 증식 억제 용도
KR101381336B1 (ko) 2012-06-25 2014-04-25 주식회사 씨티씨바이오 신규한 박테리오파지 ｐｖｐ-1 및 이의 비브리오 파라헤몰리티쿠스 증식 억제 용도
WO2013191363A1 (ko) * 2012-06-22 2013-12-27 주식회사 씨티씨바이오 신규한 박테리오파지 및 병원성 박테리아 증식 억제 용도
US8980614B2 (en) * 2012-09-06 2015-03-17 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcus haemolyticus prophage φSH2 endolysin is lytic for Staphylococcus aureus
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109312296B (zh) * 2016-06-14 2023-05-05 帝斯曼知识产权资产管理有限公司 重组酵母细胞
EP3503913A4 (en) * 2016-08-26 2020-05-27 GangaGen, Inc. STAPHTAMACTIVITY ON ORGANIC FILMS
CN106635942B (zh) * 2016-12-05 2020-05-29 齐鲁工业大学 一种芽孢表面稳定展示海藻糖合酶的工程菌及其构建方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11236314B2 (en) * 2017-03-30 2022-02-01 Bactoclear Holdings Pte. Ltd Chimeric lysm polypeptides
AU2018248060B2 (en) * 2017-04-03 2024-05-23 Sasinapas Co., Ltd. Engineered Gram-negative endolysins
CN107502603B (zh) * 2017-09-06 2018-06-05 江苏省农业科学院 一种大肠杆菌裂解酶及其制备方法与应用
CN107828769B (zh) * 2017-09-28 2021-03-02 昆明理工大学 一种耐热裂解酶MMPpgh和编码此酶的多核苷酸
CN111770687A (zh) 2017-12-14 2020-10-13 拜克多科利尔私人控股有限公司 治疗性细菌素
JP7034724B2 (ja) * 2018-01-16 2022-03-14 花王株式会社 ケラチン断片の製造方法
CN113366103A (zh) 2018-12-21 2021-09-07 诺维信公司 具有肽聚糖降解活性的多肽以及编码其的多核苷酸
CN120136980A (zh) * 2019-05-08 2025-06-13 生物技术公司 新的加德纳菌内溶素及其用途
WO2021048257A1 (en) * 2019-09-11 2021-03-18 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Bactericidal phage vectors
PL243303B1 (pl) * 2019-10-13 2023-07-31 Miedzynarodowy Inst Biologii Molekularnej I Komorkowej Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania
JP2023510074A (ja) * 2019-10-31 2023-03-13 バクトクリア ホールディングス ピーティーイー エルティーディー． 細菌の選択的溶解のためのキメラタンパク質
CN111187765B (zh) * 2020-02-17 2022-07-15 西北农林科技大学 一种反刍动物瘤胃特异溶菌酶lyz1及其应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP2024518553A (ja) * 2021-05-13 2024-05-01 フォージ バイオロジクス，インコーポレイテッド アデノウイルスヘルパープラスミド
CN116732013B (zh) * 2022-03-01 2025-07-25 百葵锐(深圳)生物科技有限公司 具有抗菌活性的细胞壁降解酶
EP4713343A2 (en) * 2023-05-15 2026-03-25 Topaz Biosciences, Inc. Enzymatically active domains from anti-staphylococcal phage proteins
EP4731683A1 (en) 2023-06-20 2026-04-29 Topaz Biosciences, Inc. Recombinant cell wall hydrolases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211281A (zh) * 1996-01-19 1999-03-17 诺沃诺尔迪斯克生物技术有限公司 用于接合的细菌供体细胞

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008553A1 (en) * 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
HUP0002662A3 (en) * 1997-07-23 2003-08-28 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
CN1355690A (zh) * 1999-04-16 2002-06-26 奥赛尔股份有限公司 一种延长可溶性病毒特异性配体在粘膜上半寿期的方法
US6831063B1 (en) * 1999-08-31 2004-12-14 The Wistar Institute Of Anatomy And Biology Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor
US20050214773A1 (en) * 2001-09-21 2005-09-29 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
JPWO2004020635A1 (ja) * 2002-08-28 2005-12-15 株式会社テクノネットワーク四国 バクテリオファージおよび細菌感染症治療剤
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
IE20060488A1 (en) 2006-06-29 2008-01-09 Teagasc Agric Food Dev Authori Recombinant staphylococcal phage lysin as an antibacterial agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211281A (zh) * 1996-01-19 1999-03-17 诺沃诺尔迪斯克生物技术有限公司 用于接合的细菌供体细胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BPI_(23)-Fcγ1重组抗菌蛋白的研究;安云庆 等;《医学研究杂志》;20030228;第32卷(第02期);20-21 *

Also Published As

Publication number Publication date
DK2037946T3 (en) 2015-04-27
US20120237491A1 (en) 2012-09-20
CA2651125C (en) 2016-06-28
ES2536852T3 (es) 2015-05-28
US10278398B2 (en) 2019-05-07
EP2037946B1 (en) 2015-02-25
JP5383481B2 (ja) 2014-01-08
EP2037946B2 (en) 2023-11-01
CN105884904A (zh) 2016-08-24
US20220053775A1 (en) 2022-02-24
US20140369986A1 (en) 2014-12-18
JP2009536033A (ja) 2009-10-08
WO2007130655A2 (en) 2007-11-15
JP2018201525A (ja) 2018-12-27
CN103436507A (zh) 2013-12-11
JP2016112020A (ja) 2016-06-23
CN101437532A (zh) 2009-05-20
EP2037946A2 (en) 2009-03-25
WO2007130655A3 (en) 2008-07-17
JP2014050388A (ja) 2014-03-20
US20170318817A1 (en) 2017-11-09
CA2651125A1 (en) 2007-11-15
JP5882968B2 (ja) 2016-03-09
PT2037946E (pt) 2015-06-04
US20190297896A1 (en) 2019-10-03
EP2037946A4 (en) 2010-09-22
JP6416803B2 (ja) 2018-10-31
JP6685360B2 (ja) 2020-04-22
US20090324576A1 (en) 2009-12-31
US8748150B2 (en) 2014-06-10
US8202516B2 (en) 2012-06-19
US9622486B2 (en) 2017-04-18
CN105884904B (zh) 2020-06-16
CN101437532B (zh) 2013-08-21
MX2008014150A (es) 2009-02-04

Similar Documents

Publication Publication Date Title
CN103436507B (zh) 噬菌体衍生的抗微生物活性剂
JP7465418B2 (ja) 治療用バクテリオシン
US9605250B2 (en) Chimeric antibacterial polypeptides
US20200017843A1 (en) Chimeric lysm polypeptides
US20190282673A1 (en) Staphtame activity on biofilms
Gouveia Recombinant antimicrobial polypeptides as alternative antibacterial agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200924

Address after: Singapore City

Patentee after: Berkeley private Holdings Ltd.

Address before: California, USA

Patentee before: GangaGen, Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

CF01 Termination of patent right due to non-payment of annual fee